Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Utah Medical Products (UTMD) Other Accumulated Expenses (2016 - 2024)

Historic Other Accumulated Expenses for Utah Medical Products (UTMD) over the last 13 years, with Q4 2024 value amounting to $2.0 million.

  • Utah Medical Products' Other Accumulated Expenses fell 523.51% to $2.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $2.0 million, marking a year-over-year decrease of 523.51%. This contributed to the annual value of $2.0 million for FY2024, which is 523.51% down from last year.
  • Per Utah Medical Products' latest filing, its Other Accumulated Expenses stood at $2.0 million for Q4 2024, which was down 523.51% from $2.1 million recorded in Q4 2023.
  • Over the past 5 years, Utah Medical Products' Other Accumulated Expenses peaked at $2.9 million during Q4 2022, and registered a low of $1.6 million during Q4 2021.
  • In the last 5 years, Utah Medical Products' Other Accumulated Expenses had a median value of $2.0 million in 2024 and averaged $2.1 million.
  • In the last 5 years, Utah Medical Products' Other Accumulated Expenses skyrocketed by 15811.17% in 2020 and then crashed by 2844.26% in 2023.
  • Quarter analysis of 5 years shows Utah Medical Products' Other Accumulated Expenses stood at $1.9 million in 2020, then fell by 16.18% to $1.6 million in 2021, then skyrocketed by 77.2% to $2.9 million in 2022, then fell by 28.44% to $2.1 million in 2023, then fell by 5.24% to $2.0 million in 2024.
  • Its Other Accumulated Expenses stands at $2.0 million for Q4 2024, versus $2.1 million for Q4 2023 and $2.9 million for Q4 2022.